Abstract
GBI Research, the leading business intelligence provider, has released its
latest research, “Gastrointestinal Disorder Therapeutics to 2016 -
High Unmet Needs Triggering Strong Growth in Crohn' s Disease and Irritable
Bowel Syndrome Markets”. It provides in-depth analysis of the unmet
needs, drivers and barriers that affect the global gastrointestinal disorder
therapeutics market. The report analyzes the markets for gastrointestinal
disorder in the US, the top five countries in Europe (the UK, Germany, France,
Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume
are forecast until 2016 for the key geographies as well as the leading
therapeutic segments. Further, the report provides competitive benchmarking
for the leading companies and analyzes the mergers, acquisitions and licensing
agreements that shape the global markets.
It is built using data and information sourced from proprietary databases,
primary and secondary research and in-house analysis by GBI Research’s
team of industry experts.
The Irritable Bowel Syndrome Market is a Fast Growing Market with Strong
Pipeline Drugs with High Safety and Efficacy Profiles
The global gastrointestinal disorder therapeutics market generated
approximately $25.6 billion in 2009. The market is anticipated to reach
revenues of approximately $17.3 billion by 2016 after declining at a CAGR of
-5.4% between 2009 and 2016. In 2010, the market is forecast to reach revenues
of about $24.5 billion. From 2001, the market grew at a CAGR of 4.4% to reach
$25.6 billion in 2009. The decline in the market is due to major drugs going
off-patent in the Gastroesophageal Reflux Disease (GERD) market. Irritable
bowel syndrome was one of the fastest growing segments. This growth is
primarily attributed to a strong pipeline with more emerging therapies. The
expected new drug launches will be priced highly and will capture a major
share of the prescriptions. Hence the irritable bowel syndrome market is
expected to reap large revenues with the increased uptake of these new drugs
and the increased awareness of the disease in patients leading to increased
treatment seeking rates at the early stages of the disease.
Increasing R&D in Gastrointestinal Disorders Segment Boosts a Strong Clinical
Pipeline
In the gastrointestinal sector, most of the companies coordinate their R&D
activities in order to constantly expand their product pipelines with
innovative drugs. Although there is a consistent and continuous threat from
generics and other alternatives, companies in the gastrointestinal disorders
sector are not reluctant to invest in R&D and are focused on offering new
products to the market. There are more than 240 drugs in the gastrointestinal
disorders pipeline. Phase II has the most pipeline drugs, accounting for 48%
of the pipeline, while the Phase III, Phase I and preclinical stages of the
pipeline accounted for 24%, 18% and 10%, respectively.
Gastrointestinal Disorder Therapeutics Market, Global, Pipeline by Phases (%),
2009
Source: GBI Research
Increasing Strategic Consolidations are Boosting the Growth of this Market
In 2008 and 2009, the gastrointestinal disorders sector witnessed numerous
licensing agreements. With about 59 drug licensing agreements, it is evident
that the gastrointestinal disorder therapeutics sector is on an enormous
growth path in the development of novel therapeutics. There have been
increasing numbers of licensing agreements for drugs in the approval stages.
Geographically, the emerging nations will see strong growth and so the number
of licensing agreements in these nations is expected to increase. Licensing
agreements strengthen the financial stability of new players in the market and
expand the potential of the major players involved in the deal.
Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements
Split by Phases (%), 1998-2010
Source: GBI Research
Licensing agreements in the approval stages accounted for 30% of the licensing
agreements. Most pharmaceutical companies find it beneficial to license a drug
in the approval stage. Most of the licensing agreements were focused on
co-promotion, distribution, adding a new product to their existing portfolio,
marketing, and receiving full marketing rights for the originator product.
Licensing agreements in the preclinical and drug discovery stage, Phase I,
Phase II and Phase III accounted for 12%, 8%, 17% and 18%, respectively, of
the licensing agreements.
Gastrointestinal Disorder Therapeutics to 2016 - High Unmet Needs Triggering
Strong Growth in Crohn' s Disease and Irritable Bowel Syndrome Markets
Summary
GBI Research' s report, “Gastrointestinal Disorders Therapeutics to 2016
- High Unmet Needs Triggering Strong Growth in Crohn' s Disease and Irritable
Bowel Syndrome Markets”, provides in-depth analysis of the unmet needs,
drivers and barriers that affect the global gastrointestinal disorder
therapeutics market. It analyzes the markets for gastrointestinal disorder
therapeutics in the US, the top five countries in Europe (the UK, Germany,
France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and
volume are forecast until 2016 for the key geographies as well as the leading
therapeutic segments. Further, the report provides competitive benchmarking
for the leading companies and analyzes the mergers, acquisitions and licensing
agreements that shape the global markets.
It is built using data and information sourced from proprietary databases,
primary and secondary research and in-house analysis by GBI Research’s
team of industry experts.
GBI Research finds that the gastrointestinal disorder therapeutics market will
decline during the period 2009-2016. This decline is primarily driven by the
negative growth of gastroesophageal reflux disease (GERD) therapeutics market
which is attributed to loss of drug patents and entry of generics. However,
other key gastrointestinal disorders such as crohn’s disease and
irritable bowels syndrome therapeutics market will continue to grow due to
strong late stage pipeline that will address the unmet needs. The global
gastrointestinal disorder therapeutics market is a highly fragmented market
and big players are facing stiff competition. The forthcoming patent expiries
of major drugs have increased the competition, driving the consolidation
further. The increasing pressure has also driven companies to enter into
licensing agreements. This allows companies to expand product portfolio and
improve their competitive positions in the market.
Scope
The scope of this report includes:
- Annualized market data for the
gastrointestinal disorder therapeutics market from 2001 to 2009, forecast
forward to 2016
- Analysis of the leading therapeutic segments. These
include crohn’s disease, ulcerative colitis, irritable bowel syndrome,
and gastroesophageal reflux disease.
- Analysis of the gastrointestinal
disorder therapeutics market in the leading geographies of the world, which
include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market
characterization of the gastrointestinal disorder therapeutics market
including market size, annual cost of therapy, and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies
studied in this report are AstraZeneca, Takeda pharmaceutical company Ltd.,
Eisai pharmaceuticals Nycomed, Pfizer Inc, GlaxoSmithKline, Novartis AG, and
Johnson & Johnson.
- Key M&A activities, licensing agreements, that have
taken place between 2008 and 2009 in the global gastrointestinal disorder
therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you
to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the
leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can
produce first in class molecules with more efficiency and better safety
-
Develop key strategic initiatives by understanding key focus areas of leading
companies
- Exploit in-licensing and out-licensing opportunities by
identifying products that could fill portfolio gaps
Table of Contents
2 Table of Contents
1 Executive Summary 1
2 Table of Contents 3
2.1 List of Tables 8
2.2 List of Figures 11
3 Global Gastrointestinal
Disorder Therapeutics Market: Scope of Research 13
3.1 Introduction 13
3.2 GBI Research Report Guidance 13
4 Global Gastrointestinal Disorder
Therapeutics Market: Market Characterization 14
4.1 Market Forecasts
14
4.2 Annual Cost of Treatment 15
4.3 Usage Patterns 16
4.3.1
Diseased Population 16
4.3.2 Treatment Seeking Population 17
4.3.3
Diagnosis Population 18
4.3.4 Prescription Population 19
4.3.5 Threapy
Usage Patterns 20
4.3.6 Geographical Distribution 21
5 Global
Gastrointestinal Disorder Therapeutics Market: US Market 22
5.1 Market
Overview 22
5.2 Market Forecasts 22
5.3 Annual Cost of Treatment
23
5.4 Usage Patterns 24
5.4.1 Diseased Population 24
5.4.2
Treatment Seeking Population 25
5.4.3 Diagnosis Population 26
5.4.4
Prescription Population 27
5.4.5 Threapy Usage Patterns 28
6 Global
Gastrointestinal Disorder Therapeutics Market: European Market 30
6.1
Market Overview 30
6.2 Market Forecasts 30
6.3 Annual Cost of
Treatment 31
6.4 Usage Patterns 32
6.4.1 Diseased Population 32
6.4.2 Treatment Seeking Population 33
6.4.3 Diagnosis Population 34
6.4.4 Prescription Population 35
6.4.5 Therapy Usage Patterns 36
7
Global Gastrointestinal Disorder Therapeutics Market : Japan Market 38
7.1
Market Overview 38
7.2 Market Forecasts 38
7.3 Annual Cost of
Treatment 39
7.4 Usage Patterns 40
7.4.1 Diseased Population 40
7.4.2 Treatment Seeking Population 41
7.4.3 Diagnosis Population 42
7.4.4 Prescription Population 43
7.4.5 Therapy Usage Patterns 44
8
Global Irritable Bowel Syndrome Therapeutics Market 46
8.1 Market Overview
46
8.2 Market Forecasts 46
8.3 Annual Cost of Treatment 48
8.4
Usage Patterns 49
8.4.1 Diseased Population 49
8.4.2 Treatment Seeking
Population 50
8.4.3 Diagnosis Population 51
8.4.4 Prescription
Population 52
8.4.5 Threapy Usage Patterns 53
8.5 Product Analysis
54
8.5.1 Lotronex (Alosetron) 54
8.5.2 Amitiza (Lubiprostone) 55
8.5.3 Colpermin (Peppermint Oil) 55
8.5.4 Bentyl (Dicyclomine
hydrochloride) 55
8.6 Drug Pipeline Analysis 56
9 Global Ulcerative
Colitis Therapeutics Market 57
9.1 Market Overview 57
9.2 Market
Forecasts 57
9.3 Annual Cost of Treatment 59
9.4 Usage Patterns 60
9.4.1 Diseased Population 60
9.4.2 Treatment Seeking Population 61
9.4.3 Diagnosis Population 62
9.4.4 Prescription Population 63
9.4.5
Threapy Usage Patterns 65
9.5 Product Analysis 66
9.5.1 Asacol 66
9.5.2 Lialda 66
9.5.3 Pentasa 66
9.5.4 Apriso 67
9.5.5 Colazal
67
9.5.6 Remicade 67
9.5.7 Azulfidine 67
9.6 Drug Pipeline
Analysis 68
10 Global GERD Therapeutics Market 69
10.1 Market Overview
69
10.2 Market Forecasts 69
10.3 Annual Cost of Treatment 71
10.4
Usage Patterns 72
10.4.1 Diseased Population 72
10.4.2 Treatment
Seeking Population 73
10.4.3 Diagnosis Population 74
10.4.4
Prescription Population 75
10.4.5 Threapy Usage Patterns 76
10.5
Product Analysis 77
10.5.1 Nexium (esomeprazole) 77
10.5.2 Aciphex
(rabeprazole sodium) 77
10.5.3 Prevacid (lansoprazole) 77
10.5.4
Prilosec (omeprazole) 78
10.5.5 Protonix (pantoprazole sodium) 78
10.5.6 Tagamet (cimetidine) 78
10.5.7 Pepcid (famotidine) 78
10.5.8
Zantac (ranitidine hydrochloride) 78
10.5.9 Axid (nizatidine) 78
10.6
Drug Pipeline Analysis 79
11 Global Crohn’s Disease Therapeutics
Market 80
11.1 Market Overview 80
11.2 Market Forecasts 81
11.3
Annual Cost of Treatment 82
11.4 Usage Patterns 83
11.4.1 Diseased
Population 83
11.4.2 Treatment Seeking Population 84
11.4.3 Diagnosis
Population 86
11.4.4 Prescription Population 87
11.4.5 Therapy Usage
Patterns 88
11.5 Product Analysis 89
11.5.1 Entocort EC (budenoside)
90
11.5.2 Humira (adalimumab) 90
11.5.3 Tysabri (natalizumab) 90
11.5.4 Remicade (infliximab) 90
11.5.5 Cimzia (cetrolizumab pegol) 91
11.6 Drug Pipeline Analysis 91
12 Global Gastrointestinal Disorder
Therapeutics Market: Market Drivers and Restraints 92
12.1 Market Drivers
92
12.1.1 Steady Increase in the Elderly Population 93
12.1.2 Stable
Increase in Incidence Rates for Gastrointestinal Disorders 93
12.1.3
Increase in Awareness Levels of Disease Progression and Etiology 93
12.2
Market Restraints 93
12.2.1 Entry of Generics Pose a Serious Problem for
Primary Manufacturers 94
12.2.2 Presence of Serious Side Effects for
Certain Classes of Therapeutic Drugs 94
13 Global Gastrointestinal
Disorder Therapeutics Market : Key Market Trends 95
14 Global
Gastrointestinal Disorder Therapeutics Market: Competitive Landscape 96
14.1 Overview 96
14.2 Competitive Profiling 96
14.3 GlaxoSmithKline,
Inc 96
14.3.1 Overview 96
14.3.2 Business Description 96
14.4
AstraZeneca 97
14.4.1 Company Overview 97
14.4.2 AZD3355 98
14.5
Pfizer Incorporated 99
14.5.1 Overview 99
14.5.2 Business Description
99
14.6 Novartis Ag 100
14.6.1 Company Overview 100
14.6.2
Business Description 100
14.7 ChemoCentryx Inc. 101
14.7.1 Overview
101
14.7.2 Gastrointestinal Disease Portfolio 101
14.7.3 Crohn’s
Disease Product Portfolio 101
14.8 Bristol-Myers Squibb 102
14.8.1
Overview 102
14.8.2 Gastrointestinal Disease Portfolio 102
14.8.3
Crohn’s Disease Product Portfolio 102
14.9 Abbott Laboratories
103
14.9.1 Overview 103
14.9.2 Gastrointestinal Disease Portfolio
103
14.9.3 Crohn’s Disease Product Portfolio 103
14.10 XenoPort,
Inc. 104
14.10.1 Company Overview 104
14.10.2 XP19986 104
14.11
Addex Pharmaceuticals 105
14.11.1 Company Overview 105
14.11.2
ADX10059 105
14.12 Vecta Ltd. (Vecta) 106
14.12.1 Company Overview
106
14.12.2 Vecam 106
14.13 Ironwood Pharmaceuticals and Forest
Laboratories 107
14.13.1 Company Overview 107
14.13.2 IBS pipeline
portfolio 108
14.14 Tioga Pharmaceuticals 109
14.14.1 Company Overview
109
14.14.2 IBS Pipeline Porfolio 109
14.15 Alimentary Health Ltd & P
& G 111
14.15.1 Company Overview 111
14.15.2 IBS Pipeline Portfolio
111
14.15.3 Bifantis (Bifidobacterium infantis 35624) 111
14.16
Lexicon 112
14.16.1 Company Overview 112
14.16.2 IBS pipeline
portfolio 112
14.16.3 LX-103 112
14.17 Salix Pharmaceuticals 113
14.17.1 Overview 113
14.17.2 Business Description 113
14.17.3 IBS
pipeline portfolio 114
Xifaxan (Rifaximin) 114
14.17.4 Ulcerative
Colitis pipeline portfolio 115
14.18 Astellas Pharma 115
14.18.1
Overview 115
14.18.2 IBS Pipeline Portfolio 115
15 Gastrointestinal
Disorder Therapeutics Market: Pipeline Analysis 118
15.1 Preclinical
119
15.2 Phase I 120
15.3 Pipeline II 122
15.4 Phase III 126
15.5 Promising Drugs under Clinical Development for Crohn’s Disease
129
15.5.1 Myoconda 129
15.5.2 Traficet-EN (CCX282) 129
15.5.3
MLN0002 (vedolizumab) 129
15.5.4 Orencia (abatacept) 129
15.5.5
ABT-874 129
15.5.6 Stelara 129
15.6 Promising Drugs under Clinical
Development for Irritable Bowel Syndrome 130
15.6.1 Linaclotide
(Linaclotide Acetate) 130
15.6.2 Asimadoline 130
15.6.3 Xifaxan
(Rifaximin) 130
15.6.4 Bifantis (Bifidobacterium infantis 35624) 130
15.6.5 LX-103 131
15.6.6 YM060 (Ramosetron hydrochloride) 131
15.7
Promising Drugs under Clinical Development for GERD 131
15.7.1 XP19986
131
15.7.2 AZD3355 131
15.7.3 ADX10059 132
15.7.4 Vecam 132
15.8 Promising Drugs under Clinical Development for Ulcerative Colitis 132
15.8.1 Prograf (Tacrolimus) 132
15.8.2 Vedolizumab 132
15.8.3
Abatacept 132
15.8.4 Adalimumab 133
15.8.5 Golimumab 133
16 Global
Gastrointestinal Disorder Therapeutics Market: Strategic Consolidations
134
16.1 Mergers and Acquisitions 134
16.1.1 Overview 134
16.1.2
GlaxoSmithKline Acquires AZ Tika Of AstraZeneca 134
16.1.3 ViroPharma
Acquires Lev Pharmaceuticals 134
16.1.4 UCB Acquires Remaining Stake In
Schwarz Pharma 134
16.1.5 Teva Pharmaceutical Acquires Bentley
Pharmaceuticals 134
16.1.6 Gilead Sciences Acquires Nycomed Limited
135
16.2 Licensing Agreements 135
16.2.1 Overview 135
17 Global
Gastrointestinal Disorder Therapeutics Market : Appendix 138
17.1 Market
Definitions 138
17.2 Abbreviations 138
17.3 Research Methodology
139
17.3.1 Coverage 139
17.3.2 Secondary Research 139
17.3.3
Primary Research 140
17.3.4 Forecasts 140
17.3.5 Expert Panel
Validation 142
17.4 Contact Us 143
17.5 Disclaimer 143
2.1
List of Tables
Table 1: Gastrointestinal Disorder Therapeutics Market,
Global, Revenue ($bn), 2001-2009 14
Table 2: Gastrointestinal
Disorder Therapeutics Market, Global, Revenue ($bn), 2009-2016 14
Table 3: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of
Treatment, 2001-2009 15
Table 4: Gastrointestinal Disorder
Therapeutics Market, Global, Annual Cost of Treatment, 2009-2016 15
Table 5: Gastrointestinal Disorder Therapeutics Market, Global, Diseased
Population, 2001-2009 16
Table 6: Gastrointestinal Disorder
Therapeutics Market, Global, Diseased Population, 2009-2016 16
Table
7: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking
Population, 2001-2009 17
Table 8: Gastrointestinal Disorder
Therapeutics Market, Global, Treatment Seeking Population, 2009-2016
17
Table 9: Gastrointestinal Disorder Therapeutics Market, Global,
Diagnosis Population, 2001-2009 18
Table 10: Gastrointestinal
Disorder Therapeutics Market, Global, Diagnosis Population, 2009-2016
18
Table 11: Gastrointestinal Disorder Therapeutics Market, Global,
Prescription Population, 2001-2009 19
Table 12: Gastrointestinal
Disorder Therapeutics Market, Global, Prescription Population, 2009-2016
19
Table 13: Gastrointestinal Disorder Therapeutics Market, Global, Usage
Patterns, 2001-2009 20
Table 14: Gastrointestinal Disorder
Therapeutics Market, Global, Usage Patterns, 2009-2016 21
Table 15:
Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn),
2001-2009 22
Table 16: Gastrointestinal Disorder Therapeutics
Market, The US, Revenue ($bn), 2009-2016 22
Table 17:
Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of
Treatment , 2001-2009 23
Table 18: Gastrointestinal Disorder
Therapeutics Market, The US, Annual Cost of Treatment, 2009-2016 23
Table 19: Gastrointestinal Disorder Therapeutics Market, The US, Diseased
Population, 2001-2009 24
Table 20: Gastrointestinal Disorder
Therapeutics Market, The US, Diseased Population, 2009-2016 24
Table
21: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Seeking
Population, 2001-2009 25
Table 22: Gastrointestinal Disorder
Therapeutics Market, The US, Treatment Seeking Population, 2009-2016
25
Table 23: Gastrointestinal Disorder Therapeutics Market, The US,
Diagnosis Population, 2001-2009 26
Table 24: Gastrointestinal
Disorder Therapeutics Market, The US, Diagnosis Population, 2009-2016
26
Table 25: Gastrointestinal Disorder Therapeutics Market, The US,
Prescription Population, 2001-2009 27
Table 26: Gastrointestinal
Disorder Therapeutics Market, The US, Prescription Population, 2009-2016
27
Table 27: Gastrointestinal Disorder Therapeutics Market, The US, Usage
Patterns, 2001-2009 28
Table 28: Gastrointestinal Disorder
Therapeutics Market, The US, Usage Patterns, 2009-2016 29
Table 29:
Gastrointestinal Disorder Therapeutics Market, Europe, Revenue ($bn),
2001-2009 30
Table 30: Gastrointestinal Disorder Therapeutics
Market, Europe, Revenue ($bn), 2009-2016 30
Table 31:
Gastrointestinal Disorder Therapeutics Market, Europe, Annual Cost of
Treatment, 2001-2009 31
Table 32: Gastrointestinal Disorder
Therapeutics Market, Europe, Annual Cost of Treatment, 2009-2016 31
Table 33: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased
Population, 2001-2009 32
Table 34: Gastrointestinal Disorder
Therapeutics Market, Europe, Diseased Population, 2009-2016 32
Table
35: Gastrointestinal Disorder Therapeutics Market, Europe, Treatment Seeking
Population, 2001-2009 33
Table 36: Gastrointestinal Disorder
Therapeutics Market, Europe, Treatment Seeking Population, 2009-2016
33
Table 37: Gastrointestinal Disorder Therapeutics Market, Europe,
Diagnosis Population, 2001-2009 34
Table 38: Gastrointestinal
Disorder Therapeutics Market, Europe, Diagnosis Population, 2009-2016
34
Table 39: Gastrointestinal Disorder Therapeutics Market, Europe,
Prescription Population, 2001-2009 35
Table 40: Gastrointestinal
Disorder Therapeutics Market, Europe, Prescription Population, 2009-2016
35
Table 41: Gastrointestinal Disorder Therapeutics Market, Europe, Usage
Patterns, 2001-2009 36
Table 42: Gastrointestinal Disorder
Therapeutics Market, Europe, Usage Patterns, 2009-2016 37
Table 43:
Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn),
2001-2009 38
Table 44: Gastrointestinal Disorder Therapeutics
Market, Japan, Revenue ($bn), 2009-2016 38
Table 45:
Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment
, 2001-2009 39
Table 46: Gastrointestinal Disorder Therapeutics
Market, Japan, Annual Cost of Treatment, 2009-2016 39
Table 47:
Gastrointestinal Disorder Therapeutics Market, Japan, Diseased Population,
2001-2009 40
Table 48: Gastrointestinal Disorder Therapeutics
Market, Japan, Diseased Population, 2009-2016 40
Table 49:
Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Seeking
Population, 2001-2009 41
Table 50: Gastrointestinal Disorder
Therapeutics Market, Japan, Treatment Seeking Population, 2009-2016
41
Table 51: Gastrointestinal Disorder Therapeutics Market, Japan,
Diagnosis Population, 2001-2009 42
Table 52: Gastrointestinal
Disorder Therapeutics Market, Japan, Diagnosis Population, 2009-2016
42
Table 53: Gastrointestinal Disorder Therapeutics Market, Japan,
Prescription Population, 2009-2016 43
Table 54: Gastrointestinal
Disorder Therapeutics Market, Japan, Prescription Population, 2001-2009
43
Table 55: Gastrointestinal Disorder Therapeutics Market, Japan, Usage
Patterns, 2001-2009 44
Table 56: Gastrointestinal Disorder
Therapeutics Market, Japan, Usage Patterns, 2009-2016 45
Table 57:
Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m),
2001-2009 47
Table 58: Irritable Bowel Syndrome Therapeutics Market,
Global, Revenue ($m), 2009-2016 47
Table 59: Irritable Bowel
Syndrome Therapeutics Market, Global, Annual Cost of Treatment,
2001-2009 48
Table 60: Irritable Bowel Syndrome Therapeutics Market,
Global, Annual Cost of Treatment, 2009-2016 48
Table 61: Irritable
Bowel Syndrome Therapeutics Market, Global, Diseased Population,
2001-2009 49
Table 62: Irritable Bowel Syndrome Therapeutics Market,
Global, Diseased Population, 2009-2016 49
Table 63: Irritable Bowel
Syndrome Therapeutics Market, Global, Treatment Seeking Population,
2001-2009 50
Table 64: Irritable Bowel Syndrome Therapeutics Market,
Global, Treatment Seeking Population, 2009-2016 50
Table 65:
Irritable Bowel Syndrome Therapeutics Market, Global, Diagnosis Population,
2001-2009 51
Table 66: Irritable Bowel Syndrome Therapeutics Market,
Global, Diagnosis Population, 2009-2016 51
Table 67: Irritable Bowel
Syndrome Therapeutics Market, Global, Prescription Population, 2001-2009
52
Table 68: Irritable Bowel Syndrome Therapeutics Market, Global,
Prescription Population, 2009-2016 52
Table 69: Irritable Bowel
Syndrome Therapeutics Market, Global, Usage Patterns, 2001-2009 53
Table 70: Irritable Bowel Syndrome Therapeutics Market, Global, Usage
Patterns, 2009-2016 54
Table 71: Ulcerative Colitis Therapeutics
Market, Global, Revenue ($m), 2001-2009 58
Table 72: Ulcerative
Colitis Therapeutics Market, Global, Revenue ($m), 2009-2016 58
Table 73: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of
Treatment , 2001-2009 59
Table 74: Ulcerative Colitis Therapeutics
Market, Global, Annual Cost of Treatment , 2009-2016 59
Table 75:
Ulcerative Colitis Therapeutics Market, Global, Diseased Population,
2001-2009 60
Table 76: Ulcerative Colitis Therapeutics Market,
Global, Diseased Population, 2009-2016 60
Table 77: Ulcerative
Colitis Therapeutics Market, Global, Treatment Seeking Population,
2001-2009 61
Table 78: Ulcerative Colitis Therapeutics Market,
Global, Treatment Seeking Population, 2009-2016 61
Table 79:
Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population,
2001-2009 62
Table 80: Ulcerative Colitis Therapeutics Market,
Global, Diagnosis Population, 2009-2016 62
Table 81: Ulcerative
Colitis Therapeutics Market, Global, Prescription Population, 2001-2009
64
Table 82: Ulcerative Colitis Therapeutics Market, Global, Prescription
Population, 2009-2016 64
Table 83: Ulcerative Colitis Therapeutics
Market, Global, Usage Patterns, 2001-2009 65
Table 84: Ulcerative
Colitis Therapeutics Market, Global, Usage Patterns, 2009-2016 66
Table 85: GERD Therapeutics Market, Global, Revenue ($m), 2001-2009
70
Table 86: GERD Therapeutics Market, Global, Revenue ($m),
2009-2016 70
Table 87: GERD Therapeutics Market, Global, Annual Cost
of Treatment, 2001-2009 71
Table 88: GERD Therapeutics Market,
Global, Annual Cost of Treatment, 2009-2016 71
Table 89: GERD
Therapeutics Market, Global, Diseased Population, 2001-2009 72
Table
90: GERD Therapeutics Market, Global, Diseased Population, 2009-2016
72
Table 91: GERD Therapeutics Market, Global, Treatment Seeking
Population, 2001-2009 73
Table 92: GERD Therapeutics Market, Global,
Treatment Seeking Population, 2009-2016 73
Table 93: GERD
Therapeutics Market, Global, Diagnosis Population, 2001-2009 74
Table 94: GERD Therapeutics Market, Global, Diagnosis Population,
2009-2016 74
Table 95: GERD Therapeutics Market, Global,
Prescription Population, 2001-2009 75
Table 96: GERD Therapeutics
Market, Global, Prescription Population, 2009-2016 75
Table 97: GERD
Therapeutics Market, Global, Usage Patterns, 2001-2009 76
Table 98:
GERD Therapeutics Market, Global, Usage Patterns, 2009-2016 77
Table
99: Crohn’s Disease Therapeutics Market, Global, Revenue ($m),
2001-2009 81
Table 100: Crohn’s Disease Therapeutics Market,
Global, Revenue ($m), 2009-2016 81
Table 101:Crohn’s Disease
Therapeutics Market, Global, Annual Cost of Treatment, 2001-2009 82
Table 102:Crohn’s Disease Therapeutics Market, Global, Annual Cost of
Treatment, 2009-2016 82
Table 103: Crohn’s Disease
Therapeutics Market, Global, Diseased Population, 2001-2009 83
Table
104: Crohn’s Disease Therapeutics Market, Global, Diseased Population,
2009-2016 83
Table 105: Crohn’s Disease Therapeutics Market,
Global, Treatment Seeking Population, 2001-2009 85
Table
106:Crohn’s Disease Therapeutics Market, Global, Treatment Seeking
Population, 2009-2016 85
Table 107:Crohn’s Disease
Therapeutics Market, Global, Diagnosis Population, 2001-2009 86
Table 108:Crohn’s Disease Therapeutics Market, Global, Diagnosis
Population, 2009-2016 86
Table 109:Crohn’s Disease
Therapeutics Market, Global, Prescription Population, 2001-2009 87
Table 110:Crohn’s Disease Therapeutics Market, Global, Prescription
Population, 2009-2016 87
Table 111:Crohn’s Disease
Therapeutics Market, Global, Usage Patterns, 2001-2009 89
Table
112:Crohn’s Disease Therapeutics Market, Global, Usage Patterns,
2009-2016 89
Table 113: Gastrointestinal Disorder Therapeutics
Market, Global, Market Drivers, 2009 92
Table 114: Gastrointestinal
Disorder Therapeutics Market, Global, Market Restraints, 2009 93
Table
115: GlaxoSmithKline - Ulcerative Colitis Pipeline, 2009 97
Table
116: Pfizer - Ulcerative Colitis Pipeline, 2009 100
Table 117:
ChemoCentryx Inc. - Autoimmune and Gastrointestinal Disease Pipeline
Products, 2009 101
Table 118: Bristol-Myers Squibb -
Gastrointestinal Pipeline Products, 2009 102
Table 119: Abbott
Laboratories - Gastrointestinal Marketed Products, 2009 103
Table
120: Abbott Laboratories - Gastrointestinal Pipeline Products, 2009
103
Table 121: Ironwood Pharmaceuticals- IBS pipeline products, 2010
108
Table 122: Tioga Pharmaceuticals - IBS Pipeline Products, 2010
109
Table 123: Alimentary Health Ltd & P & G - IBS pipeline products, 2010
111
Table 124: Lexicon - IBS pipeline portfolio, 2010 112
Table 125:
Salix Pharmaceutical - IBS Pipeline Portfolio, 2010 114
Table 126: Salix
Pharmaceuticals - Ulcerative Colitis Pipeline, 2009 115
Table 127:
Astellas Pharma - IBS Pipeline Portfolio, 2010 115
Table
128:Gastrointestinal Disorder Therapeutics Market, Global, Preclinical
Pipeline, 2009 119
Table 129:Gastrointestinal Disorder Therapeutics
Market, Global, Phase I Pipeline, 2009 120
Table 130:Gastrointestinal
Disorder Therapeutics Market, Global, Phase II Pipeline, 2009 122
Table
131:Gastrointestinal Disorder Therapeutics Market, Global, Phase III Pipeline,
2009 126
2.2 List of Figures
Figure 1: Gastrointestinal Disorder
Therapeutics Market, Global, Pipeline by Phase (%), 2009 1
Figure 2:
Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements
Split by Phase (%), 1998-2010 2
Figure 3: Gastrointestinal Disorder
Therapeutics Market, Global, Revenue ($m), 2001-2016 14
Figure 4:
Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of
Treatment, 2001-2016 15
Figure 5: Gastrointestinal Disorder
Therapeutics Market, Global, Diseased Population, 2001-2016 16
Figure 6:
Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking
Population, 2001-2016 17
Figure 7: Gastrointestinal Disorder Therapeutics
Market, Global, Diagnosis Population, 2001-2016 18
Figure 8:
Gastrointestinal Disorder Therapeutics Market, Global, Prescription
Population, 2001-2016 19
Figure 9: Gastrointestinal Disorder Therapeutics
Market, Global, Usage Patterns, 2001-2016 20
Figure 10: Gastrointestinal
Disorder Therapeutics Market, Global, Geographical Distribution of Revenues
($bn), 2001-2016 21
Figure 11: Gastrointestinal Disorder Therapeutics
Market, The US, Revenue ($m), 2001-2016 22
Figure 12: Gastrointestinal
Disorder Therapeutics Market, The US, Annual Cost of Treatment, 2001-2016
23
Figure 13: Gastrointestinal Disorder Therapeutics Market, The US,
Diseased Population, 2001-2016 24
Figure 14: Gastrointestinal Disorder
Therapeutics Market, The US, Treatment Seeking Population, 2001-2016 25
Figure 15: Gastrointestinal Disorder Therapeutics Market, The US, Diagnosis
Population, 2001-2016 26
Figure 16: Gastrointestinal Disorder Therapeutics
Market, The US, Prescription Population, 2001-2016 27
Figure 17:
Gastrointestinal Disorder Therapeutics Market, The US, Usage Patterns,
2001-2016 28
Figure 18: Gastrointestinal Disorder Therapeutics Market,
Europe, Revenue ($m), 2001-2016 30
Figure 19: Gastrointestinal Disorder
Therapeutics Market, Europe, Annual Cost of Treatment, 2001-2016 31
Figure
20: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased
Population, 2001-2016 32
Figure 21: Gastrointestinal Disorder Therapeutics
Market, Europe, Treatment Seeking Population, 2001-2016 33
Figure 22:
Gastrointestinal Disorder Therapeutics Market, Europe, Diagnosis Population,
2001-2016 34
Figure 23: Gastrointestinal Disorder Therapeutics Market,
Europe, Prescription Population, 2001-2016 35
Figure 24: Gastrointestinal
Disorder Therapeutics Market, Europe, Usage Patterns, 2001-2016 36
Figure
25: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn),
2001-2016 38
Figure 26: Gastrointestinal Disorder Therapeutics Market,
Japan, Annual Cost of Treatment, 2001-2016 39
Figure 27: Gastrointestinal
Disorder Therapeutics Market, Japan, Diseased Population, 2001-2016 40
Figure 28: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment
Seeking Population, 2001-2016 41
Figure 29: Gastrointestinal Disorder
Therapeutics Market, Japan, Diagnosis Population, 2001-2016 42
Figure 30:
Gastrointestinal Disorder Therapeutics Market, Japan, Prescription Population,
2001-2016 43
Figure 31: Gastrointestinal Disorder Therapeutics Market,
Japan, Usage Patterns, 2001-2016 44
Figure 32: Irritable Bowel Syndrome
Therapeutics Market, Global, Revenue ($m), 2001-2016 47
Figure 33:
Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of
Treatment, 2001-2016 48
Figure 34: Irritable Bowel Syndrome Therapeutics
Market, Global, Diseased Population, 2001-2016 49
Figure 35: Irritable
Bowel Syndrome Therapeutics Market, Global, Treatment Seeking Population,
2001-2016 50
Figure 36: Irritable Bowel Syndrome Therapeutics Market,
Global, Diagnosis Population, 2001-2016 51
Figure 37: Irritable Bowel
Syndrome Therapeutics Market, Global, Prescription Population, 2001-2016
52
Figure 38: Irritable Bowel Syndrome Therapeutics Market, Global, Usage
Patterns, 2001-2016 53
Figure 39: Irritable Bowel Syndrome Therapeutics
Market, Global, Pipeline by Phases, 2009 56
Figure 40: Ulcerative Colitis
Therapeutics Market, Global, Revenue ($m), 2001-2016 58
Figure 41:
Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment,
2001-2016 59
Figure 42: Ulcerative Colitis Therapeutics Market, Global,
Diseased Population, 2001-2016 60
Figure 43: Ulcerative Colitis
Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 61
Figure 44: Ulcerative Colitis Therapeutics Market, Global, Diagnosis
Population, 2001-2016 62
Figure 45: Ulcerative Colitis Therapeutics
Market, Global, Prescription Population, 2001-2016 63
Figure 46:
Ulcerative Colitis Therapeutics Market, Global, Usage Patterns, 2001-2016
65
Figure 47: Ulcerative Colitis Therapeutics Market, Global, Pipeline by
Phases, 2009 68
Figure 48: GERD Therapeutics Market, Global, Revenue ($m),
2001-2016 70
Figure 49: GERD Therapeutics Market, Global, Annual Cost of
Treatment, 2001-2016 71
Figure 50: GERD Therapeutics Market, Global,
Diseased Population, 2001-2016 72
Figure 51: GERD Therapeutics Market,
Global, Treatment Seeking Population, 2001-2016 73
Figure 52: GERD
Therapeutics Market, Global, Diagnosis Population, 2001-2016 74
Figure 53:
GERD Therapeutics Market, Global, Prescription Population, 2001-2016 75
Figure 54: GERD Therapeutics Market, Global, Usage Patterns, 2001-2016 76
Figure 55: GERD Therapeutics Market, Global, Pipeline by Phases, 2009 79
Figure 56: Crohn’s’s Disease Therapeutics Market, Global, Revenue
($m), 2001-2016 81
Figure 57: Crohn’s’s Disease Therapeutics
Market, Global, Annual Cost of Treatment, 2001-2016 82
Figure 58:
Crohn’s’s Disease Therapeutics Market, Global, Diseased
Population, 2001-2016 83
Figure 59: Crohn’s’s Disease
Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 84
Figure 60: Crohn’s’s Disease Therapeutics Market, Global,
Diagnosis Population, 2001-2016 86
Figure 61: Crohn’s’s
Disease Therapeutics Market, Global, Prescription Population, 2001-2016
87
Figure 62: Crohn’s’s Disease Therapeutics Market, Global,
Usage Patterns, 2001-2016 88
Figure 63: Crohn’s Disease Therapeutics
Market, Global, Usage Patterns, 2009-2016 91
Figure 64:
Gastrointestinal Disorder Therapeutics Market, Global, Market Indicators, 2009
92
Figure 65: Gastrointestinal Disorder Therapeutics Market, Global, Key
Market Events, 2009-2015 95
Figure 66: Gastrointestinal Disorder
Therapeutics Market, Global, Key Market Events, 2009-2016 117
Figure 67:
Gastrointestinal Disorder Therapeutics Market, Global, Pipeline by Phase, 2009
118
Figure 68: Gastrointestinal Disorder Therapeutics Market, Global,
Pipeline by Indication, 2009 118
Figure 69: Gastrointestinal Disorder
Therapeutics Market, Global, Preclinical Pipeline by Indication, 2009 120
Figure 70: Gastrointestinal Disorder Therapeutics Market, Global, Phase I
Pipeline by Indication, 2009 122
Figure 71: Gastrointestinal Disorder
Therapeutics Market, Global, Phase II Pipeline by Indication, 2009 126
Figure 72: Gastrointestinal Disorder Therapeutics Market, Global, Phase III
Pipeline by Indication, 2009 128
Figure 73: Gastrointestinal Disorder
Therapeutics Market, Global, Licensing Agreements Split by Phases, 1998-2010
135
Figure 74: Gastrointestinal Disorder Therapeutics Market, Global,
Licensing Agreements Split by Indication, 1998-2010 136
Figure 75:
Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements
Split by Approved Date, 1998 - 2010 137
Figure 76: GBI Research
Methodology, 2010 139
Figure 77: GBI Research Market Forecasting
Methodology, 2010 142
